Rise Therapeutics

Synthetic-biology immunotherapy (private)

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Dendritic cell targetingBiologic (subtype unspecified)
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.